Latest

psychopharmacology

This shows a depressed person and a pill bottle.

·May 20, 2026·12 min read

Arthritis Drug Rescues Hard-to-Treat Depression

The anti-inflammatory drug tocilizumab can successfully induce remission in patients struggling with treatment-resistant depression.

Featured Neuroscience Psychology

·May 19, 2026·16 min read

Buprenorphin and Ketamine Combo Provide Anti-Suicidal Effect

A sequential combination of a single ketamine infusion followed by four weeks of low-dose daily buprenorphine successfully extends the antisuicidal window of ketamine from one fleeting week to over a month.

Featured Neuroscience Psychology

·May 15, 2026·10 min read

Single Psilocybin Dose Sparks Rapid Depression Remission

Can a single dose of psilocybin replace daily antidepressants? A new randomized clinical trial shows that a 25 mg dose of the psychedelic compound delivers rapid, clinically meaningful symptom reductions for common depression in just 48 hours.

This shows a woman with a digital contact lense on her eye.

Featured Neuroscience Psychology Visual Neuroscience

·May 14, 2026·6 min read

Brain-Stimulating Contact Lenses Match Prozac in Depression Study

Researchers have created transparent, flexible contact lenses that treat depression using "temporal interference" electrical stimulation. In a landmark study, the lenses restored brain connectivity and boosted serotonin by 47%, matching the performance of leading antidepressants.

Featured Neuroscience Psychology

·May 7, 2026·9 min read

Psilocybin Rebuilds the Brain’s Physical Wiring

New research from UCSF shows that a single high dose of the psychedelic compound creates lasting anatomical changes in brain tracts and "loosens" rigid thought patterns, leading to significant improvements in psychological insight and well-being that persist for over a month.

This shows a person's head and mushrooms.

Featured Neuroscience Open Neuroscience Articles Psychology

·May 7, 2026·8 min read

Psilocybin Dampens Aggression and Attack Behaviors

New research shows that low doses of the psychoactive compound can reduce high-energy aggressive behaviors in mangrove rivulus fish while keeping social communication intact, offering a new vertebrate model for studying the drug's impact on social conflict.

Featured Neuroscience Psychology

·May 1, 2026·11 min read

How Scientists Cracked the Ketamine Code for Depression

By "reverse engineering" ketamine, Weill Cornell investigators have identified a specific opioid receptor pathway and a unique receptor "cross-talk" that drives rapid antidepressant effects.

Auditory Neuroscience Featured Neuroscience Psychology

·April 20, 2026·7 min read

SSRIs May Trigger Tinnitus

A new study identifies a specific serotonin circuit that triggers the auditory system, explaining why SSRIs can worsen tinnitus and offering a new target for treatment.

This shows an illustration of colorful, psychedelic neurons.

Featured Neuroscience Psychology

·April 8, 2026·8 min read

How Science Solved the Mystery of the Psychedelic High

A massive international study identifies a universal pattern of brain activity across psilocybin, LSD, DMT, and more. Researchers found that all major psychedelics dissolve brain network boundaries, triggering global "cross-talk."

Featured Neuroscience Psychology

·March 30, 2026·8 min read

Blocking NOX-1 Extends Ketamine’s Effectiveness for Depression

Researchers have identified the NOX-1 enzyme as the reason ketamine's antidepressant effects are short-lived. By blocking NOX-1, they extended the drug's benefits from days to weeks.

Featured Neuroscience Psychology

·March 25, 2026·8 min read

ADHD Medication May Shield Against Psychosis

A massive study of 700,000 people shows that ADHD medication in childhood does not increase the risk of psychosis. In fact, starting treatment before age 13 may help protect against schizophrenia in adulthood.

This shows a scale, a pill and mushrooms.

Featured Neuroscience Psychology

·March 18, 2026·9 min read

Psychedelics Match, But Don’t Beat, Traditional Antidepressants

New research reveals that the perceived advantage of psychedelics over antidepressants disappears when the "knowledge of treatment" factor is equalized.